# A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

> **NCT04311034** · PHASE1,PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** RC48

## Key facts

- **NCT ID:** NCT04311034
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-26
- **Primary completion:** 2021-12-21
- **Final completion:** 2022-05-30
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311034, "A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04311034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*